Mark Richardson, MD
Family Medicine · Marshall, MINPI 1669449443
Payments from drug & device makers
Across 104 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$344
- GSK$270
- Astellas Pharma US Inc$179
- Novo Nordisk$145
- AstraZeneca$133
- Pfizer$127
- plus $655 from 19 others
What the payments were for
- Food & beverage$1,77396%
- Education$804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $344 |
| GSK | 14 | $270 |
| Astellas Pharma US Inc | 7 | $179 |
| Novo Nordisk | 10 | $145 |
| AstraZeneca(2 entities) | 7 | $133 |
| Pfizer | 7 | $127 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Lilly USA, LLC | 5 | $65 |
| Boehringer Ingelheim | 3 | $57 |
| Amgen(2 entities) | 4 | $57 |
| Bayer | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Novartis | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Boston Scientific | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 2 | $23 |
| Amarin Pharma, Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Corium, LLC | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,853 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $144,772 |
| MounjaroTirzepatide | 130 | $135,864 |
| TrulicityDulaglutide | 59 | $90,352 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $74,282 |
| XareltoRivaroxaban | 50 | $60,915 |
| JardianceEmpagliflozin | 25 | $31,965 |
| MyrbetriqMirabegron | 47 | $30,596 |
| JanuviaSitagliptin Phosphate | 24 | $27,260 |
| FarxigaDapagliflozin Propanediol | 24 | $24,829 |
| EntrestoSacubitril/Valsartan | 15 | $13,068 |
| Spiriva RespimatTiotropium Bromide | 19 | $12,955 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $11,495 |
| Atorvastatin Calcium | 655 | $10,392 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,910 |
| Tamsulosin Hcl | 294 | $6,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $65 | $226,217189 claims |
| PfizerEliquis | $127 | $144,772150 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $270 | $94,688106 claims |
| Johnson & JohnsonXarelto | $17 | $60,91550 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $57 | $50,96255 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $30,59647 claims |
| AstraZenecaFarxiga, Symbicort | $133 | $29,23839 claims |
| NovartisEntresto | $40 | $13,06815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Marshall
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.